Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telcagepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 1/20 | 1.00 |
| ▸ | CALCA | P06881 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telcagepant SCHEMBL1198535 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL29371277 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL13345769 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL32659727 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL13025488 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3678266 | 0.99 | CALCRL (0.99) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3678268 | 0.99 | CALCRL (0.99) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3678042 | 0.99 | CALCRL (0.97) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3678043 | 0.99 | CALCRL (0.97) | CALCRLRAMP1CALCA | |
| Telcagepant SCHEMBL3682410 | 0.96 | CALCRL (0.92) | CALCRLRAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007764-A1 | PROCESS FOR THE PREPARATION OF CGRP ANTAGONIST | Merck & Co., Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007120591-A1 | PROCESS FOR THE PREPARATION OF CGRP ANTAGONIST | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | claimed |
| US-10988472-B2 | Compounds and method for blocking transmission of malarial parasite | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190315740-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-10-17 | — | — | US | disclosed |
| WO-2010144293-A1 | SYNTHESIS OF TELCAGEPANT AND INTERMEDIATES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2010-12-16 | — | — | WO | disclosed |
| US-7829699-B2 | Process for the preparation of CGRP antagonist | MERCK SHARP & DOHME CORP. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090281306-A1 | efficient synthesis for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1 -carboxamide; salt formation of potassium salt forms; treating migraine and cluster headache | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | disclosed |
| US-20090176986-A1 | Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate | MERCK SHARP & DOHME CORP. | 2009-07-09 | — | — | US | disclosed |
| US-7452903-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070225272-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315740-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | PLK1, AURKB, AURKA | CALCRL 4447/4885RAMP1 4533/4885CALCA 4295/4885 |
| US-20090176986-A1 | Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate | CCKBR, CALCRL, CALCR | CALCRL 2/4885RAMP1 67/4885CALCA 6/4885 |
| US-10988472-B2 | Compounds and method for blocking transmission of malarial parasite | PLK1, AURKB, AURKA | CALCRL 4447/4885RAMP1 4533/4885CALCA 4295/4885 |
| US-20070225272-A1 | CGRP receptor antagonists | CCKBR, BDKRB1, BDKRB2 | CALCRL 6/4885RAMP1 187/4885CALCA 23/4885 |
| US-20090281306-A1 | efficient synthesis for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1 -carboxamide; salt formation of potassium salt forms; treating migraine and cluster headache | KCNJ2, KCNN2, KCNN1 | CALCRL 200/4885RAMP1 877/4885CALCA 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.